Management of Autoimmune Liver Diseases after Liver Transplantation

• Published in: Transplantology (Basel, Switzerland) Vol. 2; no. 2; pp. 162 - 182
• Main Authors: Barba Bernal, Romelia, Medina-Morales, Esli, Goyes, Daniela, Patwardhan, Vilas, Bonder, Alan
• Format: Journal Article
• Language: English
• Published: Birmingham MDPI AG 13.05.2021
• Subjects: Asymptomatic; autoimmune hepatitis; Biopsy; Cholangitis; Drug withdrawal; Hepatitis; Immunoglobulins; Liver diseases; Metabolism; Mortality; Patients; primary biliary cholangitis; primary sclerosing cholangitis; Pruritus; Steroids; Transplants & implants; United States > US
• ISSN: 2673-3943; 2673-3943
• DOI: 10.3390/transplantology2020016

Autoimmune liver diseases are characterized by immune-mediated inflammation and eventual destruction of the hepatocytes and the biliary epithelial cells. They can progress to irreversible liver damage requiring liver transplantation. The post-liver transplant goals of treatment include improving the recipient’s survival, preventing liver graft-failure, and decreasing the recurrence of the disease. The keystone in post-liver transplant management for autoimmune liver diseases relies on identifying which would be the most appropriate immunosuppressive maintenance therapy. The combination of a steroid and a calcineurin inhibitor is the current immunosuppressive regimen of choice for autoimmune hepatitis. A gradual withdrawal of glucocorticoids is also recommended. On the other hand, ursodeoxycholic acid should be initiated soon after liver transplant to prevent recurrence and improve graft and patient survival in primary biliary cholangitis recipients. Unlike the previously mentioned autoimmune diseases, there are not immunosuppressive or disease-modifying agents available for patients with primary sclerosing cholangitis. However, colectomy and annual colonoscopy are key components during the post-liver transplant period.